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Abstract 
Review on Myelodysplastic syndrome with isolated 
deletion of 5q 
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Clinics and pathology 
Disease 
Myelodysplastic syndrome (MDS) with isolated 
deletion of chromosome 5q is part of a group of 
clonal disorders in myeloid stem cells with 
ineffective hematopoiesis which is manifested by 
morphologic dysplasia in hematopoietic cells and 
single or bilineage cytopenia(s). It is the only MDS 
subtype defined cytogenetically in the World Health 
Organization classification system. 
Phenotype/cell stem origin 
Myeloid stem cell. 
Epidemiology 
MDS with isolated del(5q) is present in <5% of MDS 
cases (Mallo et al., 2011).  It occurs more often in 
women than in men, male:female ratio 7:3, with a 
median age of diagnosis at 65 to 70 years. 
Clinics 
Patients suffering from MDS with isolated del(5q) 
present with a macrocytic anemia, normal or 
increased platelet count and absence of significant 
neutropenia in their peripheral blood. The incidence 
of bleeding and infections is therefore low in these 
patients because of the absence of significant 
neutropenia and thrombocytopenia.  
Blood transfusion dependency is seen in patients 
with severe anemia at diagnosis but also can develop 
in other patients (Germing et al., 2012).  According 
to the Revised International Prognostic Scoring 
System (IPSS-R), MDS with isolated del(5q) are 
defined as Low- or Intermediate -1- risk subtypes 
and usually have an indolent course. 
Figure 1:  An example of a typical hypolobated 
micromegakaryocyte in a bone marrow aspirate smear. 
(Wright-Giemsa) 
Pathology 
The bone marrow is characterized by an increase in 
the number of small megakaryocytes with 
monolobulated and bilobulated nuclei. There are less 
than 1% blasts in the peripheral blood and less than 
5% blasts in the bone marrow and Auer Rods are 
absent (Arber et al., 2016). 
Treatment 
MDS patients with isolated del(5q) have a favorable 
prognosis and the majority of patients respond well 
to treatment with lenalidomide. 
del (5q) solely in Myelodysplastic syndrome Shahmarvand N, Ohgami RS 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(8) 298 
 
 
Figure 2: The karyotype in a case of MDS with isolated del(5q) showing 46,XX,del(5)(q22q35). Image courtesy of Dana Bangs, 
CG(ASCP), Stanford University. 
 
Prognosis 
This subtype of MDS has a favorable prognosis. The 
exception is when this disease is associated with 
mutations in TP53. 
Cytogenetics 
Cytogenetics morphological 
As its name implies, in this entity there is interstitial 
deletion of part of the long arm of chromosome 5 
involving 5q31-5q33. MDS with isolated del(5q) can 
still be diagnosed if there is 1 additional cytogenetic 
abnormality besides del(5q) if there is no adverse 
effect of that abnormality, as such, this excludes 
{CC: TXT:monosomy 7 or del 7(q) ID:} for instance 
(Arber et al., 2016). 
Cytogenetics molecular 
The gene specific for the defect seen in MDS with 
isolated del(5q) has been identified by RNA 
interference screening to be RPS14 (Pellagatti et al., 
2008). In addition, while patients with MDS with 
isolated del(5q) classically have a favorable 
prognosis, the presence of a TP53 mutation is of 
particular importance, this mutation predicts for 
poorer prognosis and higher risk of transformation to 
AML (Mallo et al.,2013). 
Genes involved and 
proteins 
RPS14 (ribosomal protein S14) 
Location 5q33.1 
Protein 
RPS14 is a ribosomal gene located in commonly 
deleted region (CDR) of 5q. It encodes for a protein 
required for maturation of 40S ribosomal subunits. 
Patients with MDS with del(5q) are haploinsufficient 
for RPS14 which leads to impairment of ribosome 
biogenesis and subsequent reduction of protein 
translation. 
TP53 (Tumour protein p53 (Li-
Fraumeni syndrome)) 
Location 17p13.1 
Protein 
The TP53 gene encodes for the tumor suppressor 
protein p53. In the presence of DNA -damage p53 
may be activated to fix the damage, or if the damage 
cannot be repaired p53 prevents the cell from 
dividing and signals the cell to undergo apoptosis. 
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